Detalles de la búsqueda
1.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Cell
; 185(3): 467-484.e15, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35081335
2.
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Clin Infect Dis
; 76(2): 201-209, 2023 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36196614
3.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet
; 399(10342): 2212-2225, 2022 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691324
4.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883053
5.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36729167
6.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480858
7.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33306989
8.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33220855
9.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33798499
10.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34863358
11.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34370971
12.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617777
13.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702298
14.
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a second messenger in muscarinic receptor-induced contraction of guinea pig trachea.
J Biol Chem
; 288(16): 10986-93, 2013 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-23467410
15.
Nicotinic acid adenine dinucleotide phosphate regulates skeletal muscle differentiation via action at two-pore channels.
Proc Natl Acad Sci U S A
; 107(46): 19927-32, 2010 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21041635
16.
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
Vaccine
; 41(19): 3019-3023, 2023 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37045683
17.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Lancet Microbe
; 4(11): e863-e874, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37783221
18.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis
; 23(3): 295-306, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273491
19.
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
J Infect
; 87(3): 230-241, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37331429
20.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085049